MeiraGTx (MGTX) Stock Price, News & Analysis

Company Overview

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Key Stats

• Today's Range: $5.70 to $6.02
• 50-Day Range: $4.02 to $7.10
• 52-Week Range: $3.85 to $7.60
• Volume: 246,494 shs
• Average Volume: 355,138 shs
• Market Capitalization: $454.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.50
• Consensus Rating: Buy

MeiraGTx Stock Analysis - MarketRank™

MeiraGTx scored higher than 86% of companies evaluated by MarketBeat, and ranked 156th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MeiraGTx has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MeiraGTx are expected to grow in the coming year, from ($1.19) to ($0.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MeiraGTx is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MeiraGTx is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MeiraGTx has a P/B Ratio of 4.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.12% of the outstanding shares of MeiraGTx have been sold short.

Short Interest Ratio / Days to Cover

MeiraGTx has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in MeiraGTx has recently decreased by 6.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MeiraGTx does not currently pay a dividend.

Dividend Growth

MeiraGTx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.54

Percentage of Shares Shorted

2.12% of the outstanding shares of MeiraGTx have been sold short.

Short Interest Ratio / Days to Cover

MeiraGTx has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in MeiraGTx has recently decreased by 6.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.28

News Sentiment

MeiraGTx has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for MeiraGTx this week, compared to 1 article on an average week.

Search Interest

11 people have searched for MGTX on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MeiraGTx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.40% of the stock of MeiraGTx is held by insiders.

Percentage Held by Institutions

67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MGTX Stock Analysis - Frequently Asked Questions

How have MGTX shares performed this year?

MeiraGTx's stock was trading at $7.02 at the beginning of 2024. Since then, MGTX stock has decreased by 17.1% and is now trading at $5.82.
View the best growth stocks for 2024 here.

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.45. The company had revenue of $0.28 million for the quarter, compared to analysts' expectations of $16.38 million. MeiraGTx had a negative trailing twelve-month return on equity of 146.38% and a negative net margin of 633.05%.

When did MeiraGTx IPO?

MeiraGTx (MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

Who are MeiraGTx's major shareholders?

MeiraGTx's top institutional shareholders include Knoll Capital Management LLC (1.93%), Royce & Associates LP (1.23%), Erste Asset Management GmbH (1.03%) and State Street Corp (0.89%). Insiders that own company stock include Perceptive Advisors Llc, Robert K Zeldin and Robert J Wollin.
View institutional ownership trends.

How do I buy shares of MeiraGTx?

Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MeiraGTx investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/12/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGTX
• CUSIP: N/A
• CIK: 1735438
• Web: www.meiragtx.com
• Phone: (646) 860-7985
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.50
• High Stock Price Target: $36.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +303.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-84,030,000.00
• Net Margins: -633.05%
• Pretax Margin: -633.05%
• Return on Equity: -146.38%
• Return on Assets: -53.05%

Debt

• Debt-to-Equity Ratio: 0.86
• Current Ratio: 2.34
• Quick Ratio: 2.34

Sales & Book Value

• Annual Sales: $14.02 million
• Price / Sales: 32.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.17 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 78,150,000
• Free Float: 71,588,000
• Market Cap: $454.83 million
• Optionable: Optionable
• Beta: 1.24